



Dr. Ann Hanham Joins HTG Molecular Diagnostics' Board of Directors

August 29, 2016

TUCSON, Ariz., Aug. 29, 2016 (GLOBE NEWSWIRE) -- [HTG Molecular Diagnostics](#), Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors ("Board").

Ann Hanham is a senior health care executive with experience working with both private and public companies. Dr. Hanham possesses a diverse background in global clinical and regulatory development, finance, and corporate strategy. She has extensive experience in developing pharmaceutical, diagnostic and medical device products with a proven track record of clinical and regulatory approvals, building businesses, and creating shareholder value.

"We are very honored to have Ann join our Board," said TJ Johnson, President and CEO of HTG Molecular Diagnostics. "Ann's career experience, industry knowledge and leadership capabilities will be tremendous assets for our Board and management team."

Dr. Hanham is a founding and managing partner of BAR Capital Management, LLC, an investment company. From February 2000 to November 2013, Dr. Hanham was a managing director and general partner of Burrill & Company, a life science investment firm. Prior to that, Dr. Hanham held positions of increasing responsibility in clinical and regulatory affairs and product development at various companies, including InterMune Inc., Otsuka America Pharmaceuticals, Inc., Celtrix Pharmaceuticals, Inc., and Becton Dickinson and Company. She currently serves on two other public company Boards, and has served on the Boards of Directors of 20 global companies, both private and public, throughout her distinguished career.

"I am very excited to have the opportunity to work with TJ, his team and the Board as they continue their important work in developing NGS-based molecular profiling. I believe the company's technology has the potential to revolutionize the diagnosis and delivery of targeted therapies," stated Dr. Hanham.

About HTG:

Headquartered in Tucson, Arizona, HTG's mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the potential of our technology to affect the diagnosis and delivery of targeted therapies. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop new methods and/or technologies, to successfully develop and commercialize diagnostic products, including companion diagnostic products, and to successfully markets for our products. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com

TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjohnson@htgmolecular.com

 Primary Logo

HTG Molecular Diagnostics, Inc.